US State & Federal Transparency Reporting Requirements – Nevada

Pharmaceutical Companies

• A list of HCPs to whom the pharmaceutical sales representative provided either:
• Any type of compensation with a value that exceeds $10 or
• Total compensation with a value that exceeds $100 in aggregate
• The name and manufacturer of each prescription drug for which the pharmaceutical sales representative provided a free sample to an HCP, along with the name of each person to whom a free sample was provided

Data points to be disclosed:

• Manufacturer name
• Representative State ID
• Representative First and Last Name
• Activity
• Transaction Date
• Recipient First and Last Name
• Recipient Professional Designation (a list of applicable designations are provided)
• NPI
• Zip Code of Practice
• Compensation Amount
• Compensation Type
• Sample Drug Name
• Sample Drug NDC

• This information is provided for your convenience and should not be construed as legal advice. The applicability of these requirements to your organization depends on individual circumstances. The information is not exhaustive.
• Kindly check with your legal department and do not depend solely on the information provided here. Moreover, the rules mentioned could be subject to interpretation of local authorities/courts in the applicable jurisdiction. Lastly, be mindful of the latest update mentioned above. These rules and regulations change frequently, so it is important to determine whether the information reflects that most recent changes and is still applicable.
• Reporting dates are related to the transparency obligation regarding transfers of value by pharmaceutical companies and/or medical device companies (excluding suppliers of in vitro diagnostics) to HCPs and HCOs. These often are based on laws or rules in codes of conduct of industry associations. In case it is based on codes of conduct, your company only needs to disclose the transfers of value on the mentioned due date if your company is a member of the association that follows that code.
• “Due date” means the date on which the transfers of value need to be published. For example, the deadline for submitting/sending the complete information to the authority could be before the due date e.g. to give HCPs/HCOs the opportunity to check the data companies are going to disclose.
• The information does not take into consideration (unless explicitly mentioned):
  • Transparency related to clinical trials (unless it concerns transfers of value as mentioned above)
  • Transparency related to patient organizations (unless the patient organization is considered an HCO)
• If your company is a member of MedTech/EFPIA (or if the industry association your company belongs to is a member of MedTech/EFPIA), the due dates are as mentioned above for MedTech/EFPIA (end of June), unless a law/regulation specifically states otherwise (e.g., the jurisdiction is suspended/exempted from following MedTech/EFPIA).